title: Effect of strontium-substituted biphasic calcium phosphate on inflammatory mediators production by human monocytes.
abstract: Calcium phosphate materials are widely used as bone substitutes because of their properties close to those of the mineral phase of bones. Nevertheless, after several months, calcium phosphate-based materials release particles that may be phagocytosed by monocytes, leading to an inflammatory reaction. Strontium is well known to counteract the osteoporosis process, but little is known about its effect on inflammatory processes. The purpose of this work was to study the effect of biphasic calcium phosphate (BCP) particles substituted with strontium on the inflammatory reaction. Human primary monocytes stimulated or not by lipopolysaccharide (LPS) were exposed to BCP particles containing strontium for 6 and 24 h. Inflammatory mediators (cytokines and matrix metalloproteinases (MMPs)) production was then quantified by ELISA and zymography. We observed that the presence of strontium had few effects on unstimulated cells, but it decreased the production of pro-inflammatory cytokines and the chemokine interleukin 8 in LPS-stimulated cell-conditioned medium. This work suggests for the first time that strontium may be involved in the control of inflammatory processes following BCP phagocytosis by human monocytes.
authors.affiliation: EA 4691 Biomatériaux et inflammation en site osseux (BIOS), SFR CAP-Santé (FED 4231), Université de Reims-Champagne-Ardenne, UFR Odontologie, 1 rue du Maréchal Juin, BP 138, 51685 Reims, Cedex 2, France.
authors.forename: E
authors.initials: E
authors.lastname: Buache
authors.forename: F
authors.initials: F
authors.lastname: Velard
authors.forename: E
authors.initials: E
authors.lastname: Bauden
authors.forename: C
authors.initials: C
authors.lastname: Guillaume
authors.forename: E
authors.initials: E
authors.lastname: Jallot
authors.forename: J M
authors.initials: JM
authors.lastname: Nedelec
authors.forename: D
authors.initials: D
authors.lastname: Laurent-Maquin
authors.forename: P
authors.initials: P
authors.lastname: Laquerriere
mesh_terms: D002130:Calcium Phosphates / Q000494:pharmacology*; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology*; D018836:Inflammation Mediators / Q000378:metabolism*; D007378:Interleukins / Q000096:biosynthesis; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism*; D013324:Strontium / Q000494:pharmacology*; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D002130:Calcium Phosphates; D006882:Hydroxyapatites; D018836:Inflammation Mediators; D007378:Interleukins; D019714:Tissue Inhibitor of Metalloproteinases; D014409:Tumor Necrosis Factor-alpha; C074950:hydroxyapatite-beta tricalcium phosphate; C020243:calcium phosphate; D020782:Matrix Metalloproteinases; D013324:Strontium